SYM FINANCIAL Corp Takes $320,000 Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

SYM FINANCIAL Corp acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, HoldingsChannel reports. The fund acquired 964 shares of the company’s stock, valued at approximately $320,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. R Squared Ltd purchased a new stake in shares of Medpace during the 4th quarter worth approximately $30,000. Stone House Investment Management LLC acquired a new position in Medpace during the third quarter worth $33,000. Ashton Thomas Securities LLC purchased a new stake in Medpace during the third quarter worth $37,000. Capital Performance Advisors LLP acquired a new stake in Medpace in the third quarter valued at $46,000. Finally, True Wealth Design LLC increased its position in shares of Medpace by 16,800.0% in the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock valued at $56,000 after buying an additional 168 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. William Blair reissued an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. TD Cowen dropped their price objective on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Robert W. Baird raised their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Finally, Redburn Atlantic assumed coverage on Medpace in a research report on Monday, October 14th. They issued a “buy” rating and a $404.00 price objective on the stock. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $381.44.

Medpace Trading Down 0.3 %

Shares of NASDAQ:MEDP opened at $349.15 on Monday. Medpace Holdings, Inc. has a 12-month low of $286.76 and a 12-month high of $459.77. The stock’s 50-day moving average price is $342.50 and its two-hundred day moving average price is $351.96. The firm has a market cap of $10.85 billion, a price-to-earnings ratio of 30.57, a PEG ratio of 1.76 and a beta of 1.36.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.